The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

被引:716
作者
Adams, LA
Sanderson, S
Lindor, KD
Angulo, P
机构
[1] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA
关键词
fibrosis; biopsies; progression; cirrhosis; diabetes; obesity; inflammation; ballooning; Mallory's hyaline;
D O I
10.1016/j.jhep.2004.09.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The histological course of nonalcoholic fatty liver disease (NAFLD) remains undescribed. Therefore, we examined the liver histology of NAFLD patients who had undergone sequential liver biopsies. Methods: Data on 103 patients who underwent serial liver biopsies in the absence of effective treatment were reviewed, and biopsies scored in a blind fashion. Results: Mean interval between biopsies was 3.2 +/- 3.0 years (range 0.7-21.3). Fibrosis stage apparently progressed in 37%, remained stable in 34% and regressed in 29%. Severity of steatosis, inflammation, hepatocyte ballooning and Mallory's hyaline improved significantly. Aminotransferases decreased significantly between biopsies, paralleling improvement in steatosis and inflammatory features but not fibrosis stage. The rate of fibrosis change ranged from -2.05 to 1.7 stages/year. By multivariate analysis, diabetes (P=0.007) and low initial fibrosis stage (P<0.001) were associated with higher rate of fibrosis progression, as was higher body mass index (P=0.008) when cirrhotics were excluded. Conclusions: Fibrosis in NAFLD progresses slowly over time with considerable variability in the rate of changes among patients. Changes of aminotransferases do not parallel changes in fibrosis stage. Diabetic patients with elevated BMI and low fibrosis stage are at risk for higher rates of fibrosis progression. (C) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:132 / 138
页数:7
相关论文
共 30 条
[1]
2 CASES FROM THE SPECTRUM OF NONALCOHOLIC STEATOHEPATITIS [J].
ABDELMALEK, M ;
LUDWIG, J ;
LINDOR, KD .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 (02) :127-130
[2]
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[3]
Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[4]
Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity - Studies in subjects with various degrees of glucose tolerance and insulin sensitivity [J].
Bonora, E ;
Saggiani, F ;
Targher, G ;
Zenere, MB ;
Alberiche, M ;
Monauni, T ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2000, 23 (01) :57-63
[5]
Current concepts: Liver biopsy. [J].
Bravo, AA ;
Sheth, SG ;
Chopra, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :495-500
[6]
Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions [J].
Brunt, EM ;
Janney, CG ;
Di Bisceglie, AM ;
Neuschwander-Tetri, BA ;
Bacon, BR .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (09) :2467-2474
[7]
Relative contribution of iron burden, HFE mutation and insulin resistance to fibrosis in nonalcoholic fatty liver [J].
Bugianesi, E ;
Manzini, P ;
D'Antico, S ;
Vanni, E ;
Longo, F ;
Leone, N ;
Massarenti, P ;
Piga, A ;
Marchesini, G ;
Rizzetto, M .
HEPATOLOGY, 2004, 39 (01) :179-187
[8]
Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease [J].
Caldwell, SH ;
Oelsner, DH ;
Iezzoni, JC ;
Hespenheide, EE ;
Battle, EH ;
Driscoll, CJ .
HEPATOLOGY, 1999, 29 (03) :664-669
[9]
Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1111/j.1572-0241.2003.07486.x
[10]
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497